Bladder cancer is the most frequent malignancy of the urinary system and is ranked the seventh most diagnosed cancer in men worldwide. About 70-75% of all newly diagnosed patients with bladder cancer will present disease confined to the mucosa or submucosa, the non-muscle invasive bladder cancer (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to this high rate of recurrence, patients are submitted to an intensive follow-up program that should be maintained throughout many years, or even throughout life, resulting in an expensive follow-up, with cystoscopy being the most cost-effective procedure for NMIBC screening. Currently, the gold standard procedure for detection and follow-up of NMIBC is based on the association of cystoscopy and urine cytology. As cystoscopy is a very invasive approach, over the years, many different non-invasive (both in serum and urine samples) assays have been developed in order to search genetic and protein alterations related to the development, progression and recurrence of bladder cancer. TERT promoter mutations and FGFR3 hotspot mutations are the most frequent somatic alterations in bladder cancer and constitute the most reliable biomarkers for bladder cancer. Based on these findings, an ultra-sensitive assay called Uromonitor ® was developed that corresponds to a urinebased assay capable of detecting trace amounts of the two most common alterations in NMIBC, TERT promoter and FGFR3 mutation, in urine samples. The Uromonitor ® test was performed in a cohort of 72 patients, firstly diagnosed with bladder cancer and under surveillance for NMIBC, to access its sensitivity and specificity in the detection of NMIBC recurrence. Uromonitor ® was shown to be highly sensitive and specific in detecting recurrence of bladder cancer in patients under surveillance of non-muscle invasive bladder cancer.
Introduction
Bladder cancer is the most frequent malignancy involving the urinary system and affects approximately 4 times more the male gender than the female [1] . Worldwide, bladder cancer is the seventh cancer most diagnosed in men; when both genders are considered it ranks the eleventh position [2] . Of all newly patients diagnosed with bladder cancer, around three quarters present disease confined to the mucosa or submucosa [3] , the non-muscle invasive bladder cancer (NMIBC) subtype [4] . The remaining are classified as muscle invasive bladder cancer (MIBC) reflecting their capacity to infiltrate the muscle layer of the bladder [3, 5] . The gold standard for NIMBC treatment is the transurethral resection (TUR); following TUR treatment, 70% of the NMIBC patients will recur after primary tumor removal and 10 to 20% will recur as muscle-invasive bladder cancer and with the capacity to progress and develop metastatic disease [6] [7] [8] . This high rate of recurrence requires that patients are submitted to an intensive follow-up program. Major guidelines from European Association of Urology (EAU) and Canadian Urological Association (CUA) recommend cystoscopy and urinary cytology every 3 months in the first 2 years, semi-annually during the subsequent 3 years and annually thereafter [9] .
This intensive follow-up is maintained throughout many years following the initial diagnosis and confers bladder cancer as a type of cancer with the most expensive followup; consequently, cystoscopy is the most cost-effective procedure for follow-up of NMIBC [10, 11] . Currently, the gold standard to detect bladder cancer recurrence is based on the association of cystoscopy and urine cytology [4, 5] . Cystoscopy is invasive and uncomfortable for patients due to the technical requirements of the procedure, still, it renders the more accurate diagnosis method for bladder cancer [12] . Contrarily to cystoscopy, the non-invasive urine cytology is an economical approach, easier to perform, and when high-grade tumors are considered, the sensitivity is high (84%). The major limitation of urine cytology is its overall sensitivity to detect tumor cells that decreases to 16% in low-grade tumors, precluding its use in detection of those lesions [13] . The combination of all these facts leads to the opportunity for developing new, alternative and minimally invasive methods to detect bladder cancer. As urine is in direct contact with the inner part of bladder, cells from the epithelium, including scammed cells from bladder tumors can exfoliate and be detected in urine and used to evaluate and monitor the presence of neoplasia in a non-invasive approach [14] [15] [16] [17] [18] . Over the years, many different non-invasive assays have been developed in order to search genetic and protein alterations well known to be involved in the development, progression and recurrence of bladder cancer, both in serum and urine samples with the purpose to diagnose and monitor bladder cancer [13, 14, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Some of these tests present values of sensitivity and specificity higher than urinary cytology and achieved FDA-approval for bladder cancer diagnosis. Despite high sensitivities and specificities, all these molecular assays present inconvenient rates of false positive results [34, [36] [37] [38] . False positive rates could result from several factors, including the presence of benign conditions as hematuria, cystitis, lithiasis, urinary tract infections, inflammation or even because of repeated instrumentation, such as cystoscopy [39, 40] . A meta-analysis about the performance of urinary biomarkers conclude that most of the available urinary biomarkers do not detect the presence of bladder cancer in a proportion of patients and allow false-positive results in others, more frequently in low-stage and low-grade tumors [41] . Despite their good performance when combined with each other or even with urinary cytology, more reliable biomarkers and assays are needed for earlier detection of bladder cancer recurrence, particularly in low-grade and low-stage NMIBC. Recently, telomerase reverse transcriptase (TERT) promoter mutations emerged as a novel biomarker and detected in up to 80% of bladder cancer, independently of stage or grade [30, 31, 42, 43] . TERT promoter mutations are the most common event across stages and grades in malignant bladder tumors, strongly suggesting its participation in the two major genetic pathways of urothelial tumorigenesis [30, 31] . These features point TERT promoter mutations to be considered as a useful urinary biomarker for disease monitoring and early detection of recurrence, even in low-grade NMIBC, where urinary cytology usually lacks sensitivity [30, 31, 44, 45] . TERT promoter mutations are not present in inflammatory or urinary infections, different from previously described urinary biomarkers [41, 45, 46] . TERT promoter mutations assumed a novel pivotal role, surpassing the frequency of the oncogene-activating mutations in fibroblast growth factor receptor 3 (FGFR3) gene in NMIBC [47, 48] . Cappellen et al., reported FGFR3 mutations in bladder cancer with a frequency of 35% and subsequent studies established this frequency in approximately half of the primary bladder tumors [49, 50] ; several studies report its presence in up to 80% regarding early stage and low-grade tumors, and as absent or a very rare event in high-grade and invasive tumors [51] [52] [53] [54] [55] .
Based on these findings, we developed an ultra-sensitive assay named Uromonitor ® , a urine-based test capable of detecting trace amounts of the most common alterations in NMIBC, TERT promoter and FGFR3 hotspot mutations, in urine samples.
Material and Methods

Sample collection
Urine samples
Urine samples were collected during routine urology appointments and previously to cystoscopic intervention. The samples were centrifuged in a 50 mL centrifuge tube at 300 g for 20 minutes at room temperature (15 -30ºC). Supernatant was carefully removed and pellets were stored at -80ªC until DNA extraction procedure. 
Cohort characteristics
Clinical validation
We studied a total of 139 samples corresponding to urine (n=98) and formalin-fixed paraffin-embedded (FFPE) tissues of the primary tumor and of the recurrence lesions (n=41) from a cohort of patients under follow-up after an initial diagnosis and treatment for bladder cancer. When available, FFPE tissues of the corresponding primary tumor (n=9) and/or of the recurrence lesions (n=32) were also analyzed. A case was considered positive for recurrence when the cystoscopy evaluation reported the possibility of recurrence, and malignancy was confirmed in the histological examination of the recurrence lesion in the TUR. All procedures described in this study were in accordance with national and institutional ethical standards and previously approved by Local Ethical Review Committees.
Technical validation
We studied a total of 334 samples corresponding to urine (n=97) and formalin-fixed Tissue samples DNA from FFPE tissues was retrieved from 10-µm cuts after careful manual dissection.
Slides were deparaffinized in xylene (2x 10 minutes), followed by incubation in 100% alcohol (2x 5 minutes). All tumor tissue was removed from the slides to a 1.5 mL microcentrifuge tube. DNA extraction was performed using the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Germany) following the manufacturer's instructions.
DNA quantification
DNA extracted from both sample types was quantified spectrophotometrically using Nanodrop ND-2000, and its quality was checked by analysis of 260/280nm and 260/230 nm ratios.
Uromonitor ® test
The Uromonitor® test was developed and optimized in a custom made full working procedure for the detection of TERT and FGFR3 hostpot mutations in bladder cancer tumor cells exfoliated to urine. For all the assays, the limit threshold was defined at ≥ 6.25% mutant sequences in a background of wild-type DNA. This means that in the presence of a DNA sample in which altered DNA presents less than 6.25% of total DNA present in the sample, it is not granted that the assay could detect the alteration.
Clinical validation
From an initial cohort of 98 urine samples, 72 patients were fully characterized for the alterations targeted by Uromonitor ® test. In this cohort, 22.9% of cases presented recurrence, as reported by the cystoscopy examination and confirmed by histology of the TUR biopsy(ies), whereas the remaining 77.1% were negative for recurrence, Table 2 .
Of note, 5.6% of cystoscopic examinations in our series reported a recurrence, yet the histological examination of the subsequent TUR biopsies yielded only benign and/or inflammatory changes, and no recurrence was detected in the two years of follow-up of these patients, which can be taken to indicate that these are cystoscopy false positives. Regarding the specific mutations detected in recurrence positive cases, TERT promoter mutations were detected in 53% of cases (42% presented the -124C>T and 11% with the -146C>T) and FGFR3 mutations were detected in 47% of cases (32% at codon 248 and 16 at codon 249 of FGFR3 protein).
Amongst the recurrence negative cases, the Uromonitor ® test was concordantly negative for mutations in 96.3% of cases, with the remaining 2.9% (2 cases) presenting mutations for FGFR3 in codon 248, despite negativity for recurrence. These cases have remained negative for recurrence in the 2 years follow-up, suggesting these were false positives.
On the basis of these findings, the test sensitivity was 100% and specificity was 96.3%.
The negative predictive value was 100%, and the positive predictive value was 88.9% , Table 3 .
Since test sensitivity was 100%, all recurrences were detected, irrespective of their stage and grade. The majority of recurrence positive cases were in stage Ta (46.0%), with T1
and Tis representing 23.0% and 31.0%, respectively. Regarding the grade, the majority of recurrence positive tumours were low grade (69.0%) being the remaining (31.0%) high grade cases.
Comparison of the genetic profiles between urine and recurrence lesion of the corresponding patient, 60% of the cases hold at least one of the mutations detected in urine that was also identified in the corresponding recurrence lesion, with two thirds of these cases showing additional mutations in the recurrence lesion analysis. The remaining 40% of cases rendered distinct mutations in the urine and recurrence lesion.
Discussion
TERT promoter mutations were firstly described in sporadic and familial melanoma [58, 59] and since then they were reported in several cancers, such as central nervous system (43-51%), hepatocellular carcinoma (59%), thyroid (follicular cell-derived tumors) (10%) and notably in bladder cancer (59-80%) [60] [61] [62] [63] [64] [65] . For bladder cancer, the TERT promoter mutations are independent of stage or grade [30, 31, 42, 43] and were reported in both non-muscle and muscle invasive bladder cancer. As the current treatment of patients with bladder cancer is based on a very variable analysis from pathologists, based mainly on stage and grade of the tumor, new molecular markers are needed to better characterize and classify bladder cancer patients and to select an optimal treatment for each [55, 66, 67] . For this purpose, we developed a novel real-time assay, [45] . In this series, recurrence was detected (by histologic confirmation) in 22.9% of the studied cases, a value distant from the 60 to 70% reported in the literature for NMINBC following TUR treatment [6] [7] [8] . At this moment, it remains to be elucidated the reason for this difference in the recurrence values, but we can assume that they reflect patient-related factors (age, gender, multiplicity, smoking status and adjuvant treatment) associated with recurrence frequency [68] or the restricted two year follow-up that patients were considered in this study.
The mutational state of FGFR3 oncogene in bladder cancer is considered a promising predictor for recurrence and progression of NMIBC demonstrated by the association between FGFR3 mutation in primary tumor and later in recurrence events [53, [69] [70] [71] [72] [73] . In line with previous evidence FGFR3 was detected more frequently in recurrent cases and surpassing the most common genetic event in bladder cancer the TERT promoter mutations. Still, two cases were positive for FGFR3 mutations without evidence for recurrence after the follow-up terminus that dropped the specificity of Uromonitor ® to 96.3%. More than half of the cases presented at least one mutational event and it is reported that TERT promoter and FGFR3 mutations tend to occur more frequently together than per chance; the combination of both might constitute a more reliable biomarker for NMIBC recurrence monitoring [15, 42] . In terms of the Uromonitor ® performance in comparison with other available options it presented improved features.
Reviewed by Sapre et al. [74] the sensitivity of other available options ranges from 50.0%
to 96.6%, and the tests are based in different methodologies approaches, some more technically challenging and maintaining invasive requirements for the procedure in the patients. Avoidance of invasive procedures for the patients was a concern in the test development since morbidity of cystoscopy is often underestimated and can impact on patient adherence with surveillance as low as 40% [75] . The fact that the test is conducted in urine, renders it safer for patient use and with better acceptance in comparison with conventional cystoscopy.
Overall, our study demonstrates that Uromonitor ® represents a highly sensitive and specific urine test in detecting recurrence of NMIBC, and this outstanding sensitivity was maintained in the different tumor stages and/or grades. Due to its extremely high negative predictive value, the test could potentially alternate with cystoscopy in surveillance programs, diminishing the risk of missing recurrences, and with the benefit of alleviating the number cystoscopy procedures that patients require to undergo. The rate of Uromonitor ® false positives was actually lower than the rate of cystoscopy false positives. Our results prompt us to validate these findings in an independent series, in an ongoing study with a design that includes a group of benign conditions (renal lithiasis, urinary infections, hyperplasia of the prostate or other) and a head-to-head comparison with cytology. We intent to further test it to assess its cost-effectiveness and to determine its value in patients follow-up. 
